english.prescrire.org > Prescrire International > N°153 - October 2014

n°153

October 2014

Issue Contents
Editorial

Free  Solving a treatment dilemma

p.228
Weighing the risks of drugs during pregnancy

New Products


Rivaroxaban 2.5 mg (New Indication)

p.229-232
No justification for using this anticoagulant after an acute coronary syndrome

Bedaquiline (New Drug)

p.232-234
More data needed on this dangerous antitubercular drug

Lixisenatide (New Drug)

p.234-235
Wait for conclusive results on complications of diabetes

Clevidipine (New Drug)

p.236
Hypertensive crises during surgery: no advance

INN common stem: -lutamide

p.236

Enzalutamide (New Drug)

p.237
An alternative to abiraterone after docetaxel failure

Adverse Effects


Antibiotics during childhood and inflammatory bowel disease?

p.238-239
4 epidemiological studies

Transdermal rotigotine in restless legs syndrome: impulse control disorders

p.239
Adverse effect confirmed

Triptans: beware of vasoconstrictive effects

p.240
Cardiovascular reactions

Testosterone: myocardial infarction and stroke

p.240-241
Consistent data

High-dose baclofen: withdrawal syndrome following abrupt discontinuation

p.241
To be discontinued gradually

Abiraterone: thrombocytopenia

p.241
Several dozen reports worldwide

Free  Boceprevir: serious haematological disorders

p.242
Monitoring blood cell counts is essential

Free  Colchicine: more deaths

p.242
Advanced age and renal failure are risk factors

Free  Fluorouracil: dosing errors with infusion pumps

p.242
Prevention includes double-checking

Reviews


Migraine and pregnancy

p.243-245
Choice of treatment

Triptans during pregnancy

p.244

Tuberculosis

p.245-246
Multidrug-resistant tuberculosis: treatment is empirical, for want of robust trials

COPD exacerbations: 5 days of corticosteroid therapy

p.246-247
As effective as 14 days of therapy

Modest impact of brief intervention on excessive alcohol consuption

p.247
Behavioural approaches

Outlook


Obstacles to the universal application of INNs

p.248-251
Independence of WHO INN programme must be safeguarded

Free  Premarketing trials: too few patients

p.251
Regulators are complacent

Masthead


Free  Masthead

p.226

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe